Patients cannot just stop taking cardiovascular medications because doing so needs an accurate assessment of the patient's cardiac health, which could be dangerous in the long term. As a result, cardiovascular medications hold a significant position in the healthcare sector.
Due to the large population suffering from cardiovascular disorders, the North American market has had the highest rise. Numerous cardiovascular problems have been caused by the rising frequency of both obesity and hypertension in the population. Because of the enormous population of those who suffer from hypertension, the Asia Pacific area has proven to be the fastest growing Cardiovascular Drugs Market. A further factor that increases the sales of cardiovascular medications is obesity.
Additionally, the FDA authorised Norliqva (amlodipine) oral solution in February 2022 to treat adult and paediatric hypertension in order to decrease blood pressure and prevent coronary artery disease.
Despite having the highest prevalence of hypertension and the highest risk of cardiovascular morbidity and mortality, older persons are generally undertreated for high blood pressure, according to the American College of Cardiology (BP). In the United States, figures from the National Health and Nutrition Examination Survey (NHANES) show that 70% of those over 65 have hypertension. This number will increase as our population ages. In the US, 15% of the population aged 65 or older in 2014, and by 2050, that percentage is expected to increase to 20%. The Cardiovascular Drugs Market will have additional potential to expand as a result of the rising demand for blockers.
Read More- https://cmi-latestreportorientedblogs.blogspot.com/2022/12/cardiovascular-drugs-market-upcoming.html
